CommercialCoverageLow impact
Joenja (leniolisib)
Blue Cross & Blue Shield of Mississippi·MS · Allergy & Immunology, Internal Medicine, Pediatrics +1 more·Medical Policy
Effective date
Mar 20, 2025
We identified it
Jun 20, 2026
Summary
BCBS Mississippi updated their medical policy for Joenja (leniolisib) on March 20, 2025, maintaining that it is considered not medically necessary for treating activated phosphoinositide 3-kinase delta syndrome (APDS) because other covered treatment options exist. The policy includes an exception for State Health Plan members who may have prescription drug coverage through their pharmacy benefit manager.
Action Required
Immediately: Billing team should verify formulary coverage before prescribing Joenja (leniolisib) for APDS patients. For State Health Plan members, check coverage at https://www.dfa.ms.gov/cvs-caremark and submit prior authorization requests to the pharmacy benefit manager. Document medical necessity for alternative covered treatments when Joenja is deemed not medically necessary.